The pharmacokinetics and bacteriological efficacy of N-formimidoyl thienamycin were determined in rabbits infected with Escherichia coli Ki. After a single intravenous dose of 25 mg/kg, a peak N-formimidoyl thienamycin concentration in cerebrospinal fluid (CSF) of 2.5 1/ml was ataned at 45 min. The penetration into CSF was calculated to be 31%. In animals that received continuous intravenous infusions of the drug for 9 h, the mean CSF concentration was 8.3 gg/ ml, and the CSF bactericidal titers aginst the E. coli Ki strain were from 1:16 to 1:32. This infusion produced a reduction in the numbers of E. coli in the CSF of 4 logio colony-forming units per ml. N-Formimidoyl thienamycin might prove to be useful for therapy of meningitis caused by E. coli and other susceptible bacteria.
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N-Formimidoyl thienamycin is a stable derivative ofinamycin, a novel beta-lactam antibiotic with broad antimicrobial activity. The in vitro activity of this compound encomp4sses both aerobic and anaerobic gram-positive and gram-negative microoranisms, including most strains of coliform bacilli, Pseudomonas aeruginosa, Bacteroidesfragilis, Staphylococcus aureus, and S. epidermidis (3, 4, 6, 8) . N-Formimidoyl thienamycin is also active in vitro against enterococci and Listeria monocytogenes (2) . The in vitro activity against pathogens that frequendy cause nonatal meningitis suggests that N-formimidoyl enamycin might be useful for therapy of this condition. The purpose of this investigation was to determine the penetration of N-formimidoyl thienamycin into cerebrospinal fluid (CSF) and its bacteriological ffiacy in experimental Escherichia coli Ki meningitis of rabbits.
MATULS AND METHOD
A klc. N (Fig. 1) count by 2 log10 CFU/ml in 2 h after the dose, but there was no further change in the CSF count at 4 and 6 h. The largest concentration of N-formimidoyl thienamycin measured was 2.5 ,ug/ml at 45 min, and the median CSF bactericidal titers against the infecting organism were 1:4 and 1:2 at 1 and 2 h after the dose, respectively. There was no measurable bactericidal activity at 4 and 6 h. CSF cultures in two of five animals were sterilized after a single dose of N-formimidoyl thienamycin.
In the 9-h continuous-infusion studies, the CSF E. coli counts declined 4 log10 CFU/ml, and the CSF cultures of four of six rabbits were sterile at 9 h. The concentrations of N-formimidoyl thienamycin in CSF were from 4.7 to 14.8 ,ug/ml (mean 8.3 ,ug/ml), and the bactericidal titers against the E. coli were 1:16 at 3 h and 1:32 at 6 and 9 h.
DISCUSSION
The concentrations of N-formimidoyl thienamycin in the CSF of uninfected rabbits were 0.1 ,ug/ml or less, whereas those in E. coli Klinfected animals were approximately 2.0 ,ug/ml for 45 min after a single 25-mg/kg dose and remained greater than 0.1 ,ug/ml for the 6-h study period. Based on the ratio of CSF AUC to serum AUC (x100), the penetration of N-formimidoyl thienamycin into CSF was estimated at 31%. In the 9-h continuous-infusion studies of infected animals, the CSF penetration, determined from the ratio of CSF to serum concentration (x 100), was 20%. These results indicate that this compound diffuses well into the CSF of animals with purulent meningitis. In addition, the concentrations present after continuous infusion produced a bactericidal titer against the infecting E. coli Kl strain of from 1:16 to 1:32 and reduced the bacterial count by 4 log10 CFU/ml in 9 h. Cultures of CSF at the completion of the studies were sterile in four of six animals, whereas those in six untreated animals had a median count of 106 CFU/ml.
The MBC for E. coli Kl was large compared with the MIC when determined in MuellerHinton broth (MIC -0.07 ,ug/ml; MBC = 10 ,ug/ ml), but not in dextrose phosphate broth (MIC = 1.25 ,ug/ml; MBC = 2.5 ,ug/ml). The influence of the medium on N-formimidoyl thienamycin susceptibilities has been previously reported by Eliopoulos and Moellering (2) . Our data from the meningitis model suggest that the infecting E. coli Kl strain was not clinically tolerant because a large reduction in the CSF bacterial count occurred, despite the fact that only 20%o of the CSF samples contained concentrations of Nformimidoyl thienamycin that exceeded the MBC (determined in Mueller-Hinton broth) of the pathogens.
Based on the results from these experimentally infected rabbits, N-formimidoyl thienamycin might be useful for therapy of meningitis caused by E. coli and other susceptible bacteria. Unpublished data from our laboratory showed that of 63 gram-negative enteric bacillary strains from CSF cultures of neonates (from the Neonatal Meningitis Cooperative Studies), all were inhibited by 0.6 ,ug/ml, and all of 30 group B streptococcal strains from CSF were inhibited by 0.02 ,ug of N-formimidoyl thienamycin per ml. Because these microorganisms are the principal pathogens of neonatal meningitis, it is possible that N-formimidoyl thienamycin will have a role in the treatment of this condition.
